MBX Biosciences, Inc. Share Price & Technical Analysis
MBX · $31.85 (+0.19%)
Healthcare / Biotechnology
$31.85
+0.19%
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also develo…
Price chart
Seasonality
May has 2 positive and 0 negative years (last 3 years shown)
6% return in May, 18% avg return in past 3 year May month.
5% return in 2026, 42% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 16% | -12% | -4% | 0% | 6% | – | – | – | – | – | – | – | 5% |
| 25 | -47% | -2% | -20% | 44% | 18% | -9% | 16% | 16% | 16% | 22% | 57% | -8% | 102% |
| 24 | – | – | – | – | – | – | – | – | 13% | -10% | -12% | -10% | -19% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.75B
P/E ratio
—
52W high
$45.85
52W low
$9.43
Volume
4,36,084
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is MBX Biosciences, Inc. share price today?
- MBX Biosciences, Inc. (MBX) last traded around $31.85 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MBX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MBX. Download the app for real-time alerts.
- How can I analyze MBX Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.